Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline in Progressive Supranuclear Palsy (Phase III)
2008-007520-26Phase 3Terminated
- Sponsor
- LMU Klinikum
- Start
- Nov 2009
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing Rasagiline with Placebo (2 arms). Primary endpoint: Integral of PSPRS changes from baseline over 12 months. Started Nov 2009; status: terminated.
02
Drugs
rasagiline
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on 2008-007520-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007520-26.